ArticleHuman mutation2026
Hypoxia-Associated Molecular Subtypes Reveal Immune Checkpoint, Ferroptosis, and m6A Regulatory Heterogeneity in Pediatric Vasculitis.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vasculitis is a heterogeneous inflammatory vascular disorder with substantial clinical and molecular diversity. However, hypoxia-associated molecular subtypes in pediatric vasculitis and their differences from adult vasculitis remain poorly defined. Methods: Transcriptomic data of pediatric and adult vasculitis were obtained from the GEO database. RNA-seq data from GSE129752 were normalized by log Results: Consensus clustering separated pediatric vasculitis into two hypoxia-associated subtypes, high hypoxia pediatric vasculitis population (high_hypoxia group) and low hypoxia pediatric vasculitis population (low_hypoxia group), with distinct transcriptomic profiles. High_hypoxia group showed higher expression of multiple immune checkpoint genes, including HAVCR2, IGSF8, ITPRIPL1, LAG3, PDCD1, SIGLEC15, and TIGIT. Ferroptosis-related genes EMC2 and ATP5MC3 were also elevated in the high_hypoxia group. In addition, most m6A regulators, including FTO, METTL14, WTAP, and RBM15, were significantly upregulated in the high_hypoxia group. Comparison between pediatric and adult vasculitis identified 85 differentially expressed genes, including 21 upregulated and 64 downregulated genes in pediatric vasculitis. Functional enrichment suggested that pediatric vasculitis was associated with fibroblast proliferation and vascular remodeling, whereas adult vasculitis was enriched in immature T-cell regulation and fatty acid transport. Germline mutation-related genes, including VHL, BRCA1, RET, and MUTYH, showed coordinated correlations with age-related vasculitis. Conclusion: Hypoxia-associated molecular heterogeneity exists in pediatric vasculitis and we observed age-related transcriptomic differences between pediatric and adult disease. These findings provide a foundation for precision classification and future mechanism-based therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.